Pfizer Hacking & Pharma Ineptness: Meyer Explains
Last week, the Pfizer Facebook page was hacked by ScriptKiddies, setting off a flurry of chatter about not just hacking, but the extent to which this episode would affect the way drugmakers view the virtues of Facebook and, beyond that, social media (back story). This happened just as Facebook changes it rules so that drugmakers […]
Read More »Category : News
Kindler Undone: The Dysfunctional Pfizer Culture
For those curious as to what went down before Jeff Kindler unexpectedly resigned last December as the Pfizer ceo, a new treatise in Fortune magazine offers a behind-the-scenes look at the political infighting, overblown aspirations and inept calculations that contributed to his demise, as well as a decade of disappointment and a few spectacular failures […]
Read More »Category : News
Kindler Undone: The Dysfunctional Pfizer Culture
For those curious as to what went down before Jeff Kindler unexpectedly resigned last December as the Pfizer ceo, a new treatise in Fortune magazine offers a behind-the-scenes look at the political infighting, overblown aspirations and inept calculations that contributed to his demise, as well as a decade of disappointment and a few spectacular failures […]
Read More »Category : News
Is AstraZeneca Overcharging For Its Bloodthinner?
File this under a not-so Brilinta move? Now, that the FDA has finally approved Brilinta, a bloodthinner developed by AstraZeneca that had to overcome a curious hurdle, the drugmaker has set its pricing. But one Wall Street analyst questions whether AstraZeneca may have priced itself out of the market. To wit, Brilinta will cost about […]
Read More »Category : News
Clinical Trial Costs Are Rising Rapidly
As drugmakers scramble to replenish their pipelines, they are encountering all sorts of difficulties, including rising costs for clinical trials. And this is happening across all phases. Why? There is increasing competition for trial sites and clinical research organizations that can yield reliable, high quality data, according to a recent survey. And so, 32 percent […]
Read More »Category : News
A Valeant Pharma Unit Has Problems Making Drugs
Valeant Pharmaceuticals has been on an acquisition spree, but perhaps the Canadian drugmaker may want to conduct a bit more due diligence before its next purchase. One of its recent deals was for Sanitas, which is based in Lithuania and controls Jelfa, another drugmaker based in Poland and that actually produces much of the Sanitas […]
Read More »Category : News
FDA Says CRO Studies Should Be Reevaluated
This is every drugmaker’s nightmare. The pharmaceutical industry has been put on alert by the FDA that any clinical tests conducted between April 2005 and June 2010 by a contract research organization called Cetero Research may have to be reevaluated because two FDA inspections and an outside audit found falsified data and manipulated samples. There […]
Read More »Category : News
HHS To Boost Protections In Clinical Trials
After two decades during which complaints have mounted over various aspects of clinical trials, the US Department of Health & Human Services has issued a proposal that would, presumably, better protect clinical trial subjects. There are various suggestions, but include improving consent forms for participants and mandating the use of a single institutional review board […]
Read More »Category : News
DaVita Wasted Drugs To Make Big $$ Off Medicare
One of the biggest providers of kidney dialysis deliberately wasted medicine in order to gain hundreds of millions of dollars in extra payments from Medicare, according to a whistleblower lawsuit filed by a former clinic nurse and doctor. They claim DaVita used unnecessarily large vials of different meds because Medicare would pay for unused portions […]
Read More »Category : News
Forest Hires Former Senator To Fight The Feds
Faced with being banned from doing business with such federal healthcare programs as Medicare and Medicaid, Forest Laboratories ceo and president Howard Solomon recently retained former US Senator John Breaux as a lobbyist. The Louisiana pol is now a senior counsel with the Patton Boggs law firm, which has a large healthcare practice. New Webinar, […]
Read More »Category : News
